Investors

BioTime is a clinical-stage biotechnology company committed to delivering novel products based on regenerative medicine to patients with serious diseases and degenerative conditions for which there presently are no cures.

Presentation Will Describe the Future of Aging Research and iTRTM,
an Emerging Area of Research from BioTime
Dr. West to also Serve on Panel: “Unleashing Regenerative Medicine to
Extend the Healthy Lifespan”
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 8, 2016--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that Co-Chief Executiv...

-Will Also Present at Young Jewish Professionals Life Sciences &
Pharmaceuticals CEO Symposium-
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 10, 2016--
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company
with a focus on pluripotent stem cell technologies, today announced that
Co-Chief Executive Officer Michael D. West, Ph.D., is participating at
two conferences during the week of November 14.
On Monday, November 14, Dr. ...

DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.

Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.